Covid 19 Research using Clinical Trials (Home Page)
Report for D011565: Psoriasis NIH
(Synonyms: Psori, Psorias, Psoriasi, Psoriasis)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug741 | Nasopharyngeal swab Wiki | 0.71 |
| drug431 | Favipiravir Wiki | 0.32 |
| drug872 | Placebos Wiki | 0.25 |
There is one clinical trial.
Clinical Trials
1 Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
NCT04324866 Coronavirus Infection Diagnostic Test: Nasopharyngeal swab MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Psoriasis
HPO:Palmoplantar pustulosis Psoriasiform dermatitis
Primary Outcomes
Measure: Point prevalence of COVID-19 infection Time: Baseline up to 6 months
Secondary Outcomes
Measure: Incidence of COVID-19 infection Time: Baseline up to 6 months
Measure: Percentage of subjects presenting fever or respiratory symptoms Time: Baseline up to 6 months
Measure: Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments Time: Baseline up to 6 months
Measure: Evaluate the relationship between COVID-19 infection and comorbid medical conditions Time: Baseline up to 6 months
HPO Nodes
Primary Outcomes
Measure: Point prevalence of COVID-19 infection Time: Baseline up to 6 monthsSecondary Outcomes
Measure: Incidence of COVID-19 infection Time: Baseline up to 6 monthsMeasure: Percentage of subjects presenting fever or respiratory symptoms Time: Baseline up to 6 months
Measure: Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments Time: Baseline up to 6 months
Measure: Evaluate the relationship between COVID-19 infection and comorbid medical conditions Time: Baseline up to 6 months